Alessandria G, Meli R, Infante MT et al (2020) Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: a pilot study. Clin Neurol Neurosurg 196:105990. https://doi.org/10.1016/J.CLINEURO.2020.105990

Article  PubMed  Google Scholar 

Almeida CMO, Brito MMC, Bosaipo NB et al (2021) Cannabidiol for rapid eye movement sleep behavior disorder. Mov Disord 36:1711–1715. https://doi.org/10.1002/mds.28577

Article  CAS  PubMed  Google Scholar 

Anis S, Zalomek C, Korczyn AD et al (2022) Medical Cannabis for Gilles de la Tourette Syndrome: an open-label prospective study. Behav Neurol. https://doi.org/10.1155/2022/5141773

Article  PubMed  PubMed Central  Google Scholar 

Artukoglu BB, Bloch MH (2019) The potential of Cannabinoid-based treatments in Tourette syndrome. CNS Drugs 33:417–430. https://doi.org/10.1007/s40263-019-00627-1

Article  CAS  PubMed  Google Scholar 

Belgers V, Röttgering JG, Douw L et al (2023) Cannabinoids to improve health-related quality of life in patients with neurological or oncological disease: a meta-analysis. Cannabis Cannabinoid Res 8:41–55. https://doi.org/10.1089/CAN.2021.0187

Article  PubMed  PubMed Central  Google Scholar 

BfArM (2022a) Abschlussbericht der Begleiterhebung nach § 31 Absatz 6 des Fünften Buches Sozialgesetzbuch zur Verschreibung und Anwendung von Cannabisarzneimitteln

BfArM (2022b) Anhang 1 zum Abschlussbericht: Ergänzende Informationen zu den Fragen 1 bis 14 der Begleiterhebung

Bhunia S, Kolishetti N, Arias AY et al (2022) Cannabidiol for neurodegenerative disorders: a comprehensive review. Front Pharmacol 13:989717. https://doi.org/10.3389/fphar.2022.989717

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bialas P, Fitzcharles MA, Klose P, Häuser W (2022) Long-term observational studies with cannabis-based medicines for chronic non-cancer pain: a systematic review and meta-analysis of effectiveness and safety. Eur J Pain (united Kingdom) 26:1221–1233. https://doi.org/10.1002/EJP.1957

Article  Google Scholar 

Black N, Stockings E, Campbell G et al (2019) Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry 6:995–1010. https://doi.org/10.1016/S2215-0366(19)30401-8

Article  PubMed  PubMed Central  Google Scholar 

Bourque J, Potvin S (2021) Cannabis and cognitive functioning: from acute to residual effects, from randomized controlled trials to prospective designs. Front Psychiatry 12:596601. https://doi.org/10.3389/FPSYT.2021.596601/BIBTEX

Article  PubMed  PubMed Central  Google Scholar 

Brucki SMD, Adoni T, Almeida CMO et al (2021) Cannabinoids in neurology—position paper from scientific departments from Brazilian Academy of Neurology. Arq Neuropsiquiatr 79:354–369. https://doi.org/10.1590/0004-282x-anp-2020-0432

Article  PubMed  PubMed Central  Google Scholar 

Buhmann C, Gerloff C (2013) Autofahren Bei Morbus Parkinson. Aktuelle Neurologie 40:315–320. https://doi.org/10.1055/s-0033-1349884

Article  Google Scholar 

Bundestag D (2017) Deutscher Bundestag. Gesetz zur Änderung betäubungsmittel-rechtlicher und anderer Vorschriften (06. März 2017)

Kassenärztliche Bundesvereinigung (2023) Arzneimittel-Verordnung. Cannabis—was Ärzte bei der Verordnung wissen müssen

Carod-Artal FJ, Adjamian P, Vila Silván C et al (2022) A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis. Expert Rev Neurother 22:499–511. https://doi.org/10.1080/14737175.2022.2075263

Article  CAS  PubMed  Google Scholar 

Carroll CB, Bain PG, Teare L et al (2004) Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 63:1245–1250. https://doi.org/10.1212/01.WNL.0000140288.48796.8E

Article  CAS  PubMed  Google Scholar 

Chagas MHN, Zuardi AW, Tumas V et al (2014) Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. J Psychopharmacol 28:1088–1098. https://doi.org/10.1177/0269881114550355

Article  CAS  PubMed  Google Scholar 

Consroe P, Sandyk R, Snider SR (1986) Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 30:277–282. https://doi.org/10.3109/00207458608985678

Article  CAS  PubMed  Google Scholar 

Consroe P, Laguna J, Allender J et al (1991) Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav 40:701–708. https://doi.org/10.1016/0091-3057(91)90386-G

Article  CAS  PubMed  Google Scholar 

Cravanas B, Frei K (2020) The effects of Cannabis on hallucinations in Parkinson’s disease patients. J Neurol Sci 419:117206. https://doi.org/10.1016/j.jns.2020.117206

Article  PubMed  Google Scholar 

Cristino L, Bisogno T, Di Marzo V (2020) Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol 16:9–29. https://doi.org/10.1038/s41582-019-0284-z

Article  PubMed  Google Scholar 

Curtis A, Mitchell I, Patel S et al (2009) A pilot study using nabilone for symptomatic treatment in Huntington’s disease. Mov Disord 24:2254–2259. https://doi.org/10.1002/MDS.22809

Article  PubMed  Google Scholar 

de Almeida CMO, Brito MMC, Bosaipo NB et al (2023) The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson’s Disease Patients with REM Sleep Behavior Disorder: a Post Hoc Exploratory Analysis of Phase 2/3 Clinical Trial. Cannabis Cannabinoid Res. https://doi.org/10.1089/CAN.2021.0158

Article  PubMed  PubMed Central  Google Scholar 

Devinsky O, Cross JH, Laux L et al (2017) Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med 376:2011–2020. https://doi.org/10.1056/NEJMoa1611618

Article  CAS  PubMed  Google Scholar 

Elliott J, DeJean D, Clifford T et al (2019) Cannabis-based products for pediatric epilepsy: a systematic review. Epilepsia 60:6–19. https://doi.org/10.1111/epi.14608

Article  PubMed  Google Scholar 

Erga AH, Maple-Grødem J, Alves G (2022) Cannabis use in Parkinson’s disease—a nationwide online survey study. Acta Neurol Scand 145:692–697. https://doi.org/10.1111/ane.13602

Article  PubMed  Google Scholar 

Feeney MP, Bega D, Kluger BM et al (2021) Weeding through the haze: a survey on cannabis use among people living with Parkinson’s disease in the US. NPJ Parkinsons Dis 7:21. https://doi.org/10.1038/s41531-021-00165-y

Article  PubMed  PubMed Central  Google Scholar 

Fife TD, Moawad H, Moschonas C et al (2015) Clinical perspectives on medical marijuana (cannabis) for neurologic disorders. Neurol Clin Pract 5:344–351. https://doi.org/10.1212/CPJ.0000000000000162

Article  PubMed  PubMed Central  Google Scholar 

Filippini G, Minozzi S, Borrelli F et al (2022) Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD013444.PUB2/MEDIA/CDSR/CD013444/IMAGE_N/NCD013444-CMP-001.19.SVG

Article  PubMed  PubMed Central  Google Scholar 

Fisher E, Moore RA, Fogarty AE et al (2021) Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain 162:S45–S66. https://doi.org/10.1097/J.PAIN.0000000000001929

Article  CAS  PubMed  Google Scholar 

Fox SH, Kellett M, Moore AP et al (2002) Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 17:145–149. https://doi.org/10.1002/MDS.1280

Article  PubMed  Google Scholar 

Frankel JP, Hughes A, Lees AJ, Stern GM (1990) Marijuana for parkinsonian tremor. J Neurol Neurosurg Psychiatry 53:436. https://doi.org/10.1136/jnnp.53.5.436

Article  CAS  PubMed  PubMed Central  Google Scholar 

Freidel M, Tiel-Wilck K, Schreiber H et al (2015) Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability. Acta Neurol Scand 131:9–16. https://doi.org/10.1111/ANE.12287

Article  CAS  PubMed  Google Scholar 

Gado F, Digiacomo M, Macchia M et al (2018) Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis. Medicines 5:91. https://doi.org/10.3390/medicines5030091

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gauter B, Rukwied R, Konrad C (2004) Cannabinoid agonists in the treatment of blepharospasm–a case report study. Neuro Endocrinol Lett 25:45–48

PubMed  Google Scholar 

Grotenhermen F, Häußermann K (2017) Cannabis Verordnungshilfe für Ärzte

Haroutounian S, Arendt-Nielsen L, Belton J et al (2021) International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. Pain 162:S117–S124. https://doi.org/10.1097/J.PAIN.0000000000002266

Article  PubMed  PubMed Central  Google Scholar 

Hasbi A, Madras BK, George SR (2023) Endocannabinoid system and exogenous cannabinoids in depression and anxiety: a review. Brain Sci 13:325. https://doi.org/10.3390/brainsci13020325

Article  CAS  PubMed  PubMed Central